OncoMatch/Clinical Trials/NCT05968690
Naltrexone and Propranolol Combined With Immunotherapy
Is NCT05968690 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Propranolol and Naltrexone for advanced melanoma.
Treatment: Propranolol · Naltrexone — Various forms of stress can promote cancer development and growth and negatively impact the immune system's response to tumors. Beta-adrenergic and opioid receptors co-exist in many cells including immune cells and are integral components of the body's response to stress. Pre-clinical studies have demonstrated that dual blockade of these receptors can decrease tumor growth and modulate the anti-tumor immune response. This clinical trial investigates the safety and potential therapeutic benefits of combining a beta-adrenergic blocker (propranolol) and an opioid receptor antagonist (naltrexone) with immune checkpoint inhibitors in patients with advanced melanoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: investigational agent
Receipt of any other investigational agents or participation in a study of an investigational agent or use of an investigational device within four weeks of the first dose of treatment.
Lab requirements
Blood counts
ANC >1500/mcL; platelets >100,000/mcL; hemoglobin >9 g/dL; albumin >2.5 mg/dL
Liver function
AST and ALT <2.5x ULN; serum total bilirubin <1.5x ULN or direct bilirubin < ULN for subjects with total bilirubin >1.5x ULN.
Normal organ function, defined as: 1. Absolute neutrophil count (ANC) >1500/mcL 2. Platelets >100,000/mcL 3. Hemoglobin (Hb) >9 g/dL 4. Albumin >2.5 mg/dL 5. AST and ALT <2.5x ULN 6. Serum total bilirubin <1.5x ULN or direct bilirubin < ULN for subjects with total bilirubin >1.5x ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Rutgers Cancer Institute of New Jersey · New Brunswick, New Jersey
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05968690 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior investigational agent disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages